1. Germany Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bayer AG

Bayer AG

44.28
EUR
+0.38
(+0.87%)
-1.74EPS
47.36BMarket Cap
Nov 03Next Earn
Bayer AG
MIL:1BAYN
(Euronext Milan)

Recent

price

44.28

P/E

ratio

- -

div

yld

0.30%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
42.43
44.17
48.06
48.56
49.99
55.73
41.97
39.56
39.06
44.36
42.14
44.87
51.65
48.49
47.44
46.39
46.19
Revenue per Share
1.57
2.99
2.91
3.86
4.14
4.97
5.44
8.29
1.8
4.17
-10.68
1.02
4.22
-2.99
-2.6
-3.68
-1.77
Basic EPS, GAAP
5.15
4.17
3.15
3.64
4.16
5.29
7.82
6.52
5.66
5.66
2.53
2.52
4.22
2.41
4.67
3.5
2.12
Free Cash Flow per Basic Share
1.4
1.5
1.65
1.9
2.1
2.26
2.55
2.67
2.56
2.66
2.82
2.03
2.02
2.42
0.13
0.13
0.13
Dividend per Share
22.41
22.86
21.96
24.66
23.93
28.88
36.1
43.79
49.21
48.1
31.07
33.61
39.47
33.52
32.48
26.41
30.11
Book Value per Share
-1.58
-0.29
-0.36
2.31
-12.96
-8.34
0.54
12.35
-31.56
-27.25
-31.88
-33.94
-25.51
-23.14
-20.58
-23.14
-20.13
Tangible Book Value per Share
827
827
827
827
827
827
833
885
941
982
982
982
982
982
982
982
982
Basic Weighted Avg Shares
35,088
36,528
39,741
40,157
41,339
46,085
34,943
35,015
36,742
43,545
41,400
44,081
50,739
47,637
46,606
45,575
45,375
Sales/Revenue/Turnover
7.78
11.62
13.2
12.68
13.59
14.74
17.22
17.45
-0.5
10.82
-1.72
15.67
14.45
16.87
7.14
13.47
17.98
Operating Margin (%)
3,556
2,769
2,988
2,896
2,920
3,332
3,063
2,660
6,241
5,367
13,259
3,056
6,503
10,020
8,783
2,785
3,751
Depreciation Expense
1,301
2,470
2,403
3,189
3,426
4,110
4,531
7,336
1,695
4,091
-10,495
1,000
4,150
-2,941
-2,552
-3,620
-1,738
Net Income, GAAP
23.88
26.49
22.76
24.27
24.26
23.36
21.31
29.04
26.3
15.53
- -
50.05
10.79
- -
- -
- -
- -
Effective Tax Rate (%)
3.71
6.76
6.05
7.94
8.29
8.92
12.97
20.95
4.61
9.39
-25.35
2.27
8.18
-6.17
-5.48
-7.94
-3.83
Profit Margin (%)
7,483
6,678
5,906
5,005
6,724
6,841
11,910
16,480
7,820
9,224
-1,093
3,175
2,676
8,099
5,492
326
1,374
Working Capital
9,582
7,686
6,706
5,044
17,797
16,332
15,375
12,158
37,708
36,907
33,198
36,478
33,781
38,170
35,491
31,806
- -
LT Debt
18,896
19,271
18,551
20,804
20,218
25,445
31,897
36,861
46,064
47,433
30,675
33,168
38,926
33,078
32,045
26,063
29,708
Total Equity
6.8
10.11
10.55
13.36
12.19
11.21
11.48
8.24
4.19
4.21
- -
2.29
8.67
- -
- -
- -
- -
Return on Invested Capital (%)
4.24
10.81
10.78
13.96
12.22
11.75
10.46
14.36
4.14
6.51
- -
2.28
7.57
- -
- -
- -
- -
Return on Capital (%)
6.9
12.98
12.76
16.28
16.78
18.53
16.6
21.85
4.1
8.78
-26.99
3.15
11.56
-8.2
-7.87
-12.51
-5.8
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,647
- -
- -
LT Borrowings
30,779
- -
- -
LT Finance Leases
1,027
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
982
982
982
Market Capitalization
36,055
38,771
47,363

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
32,911
35,301
33,644
Cash, Cash Equivalents & STI
7,856
6,660
5,082
Accounts Receivable, Net
9,077
12,907
12,880
Inventories
12,335
12,014
11,971
Total Current Liabilities
32,585
33,460
32,270
Payables & Accruals
- -
- -
- -
ST Debt
4,647
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.26%
-18.67%
Free Cash Flow
7.19%
18.61%
-24.99%
Net Income, GAAP
-15.67%
12.64%
41.85%
Sales/Revenue/Turnover
0.57%
2.22%
-2.21%
Total Cash Common Dividend
-6.48%
-21.22%
-3.05%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,765
11,144
9,968
11,729
46,606
2025
13,738
10,739
9,660
11,438
45,575
2026
13,405
10,872
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.04
-0.03
-4.26
-0.34
-2.6
2025
1.32
-0.2
-0.98
-3.82
-3.68
2026
2.81
0.22
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
0.01
0.01
0.13
2025
- -
0.11
0.01
0.01
0.13
2026
- -
0.11
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bayer AG Bayer Aktiengesellschaft (BAYN.DE) is a German multinational life sciences company that develops, manufactures and markets products in pharmaceuticals; consumer health, including non-prescription medicines, nutritional supplements, skincare, digestive health and self-care solutions; and crop science, encompassing crop protection products such as fungicides, herbicides and insecticides, seeds, traits and digital farming technologies. Pharmaceuticals focuses on prescription medicines in cardiology, oncology, hematology, women's health, ophthalmology and radiology, featuring key brands including Nubeqa (darolutamide), Kerendia (finerenone), Xarelto (rivaroxaban), Eylea (aflibercept), Adempas (riociguat) and the Mirena intrauterine device family; consumer health offers over-the-counter products like Aspirin, Aleve, Berocca and Rennie for pain relief, allergy, cough and cold, dermatology and cardiovascular risk prevention; while crop science provides solutions like Liberty herbicide, Nativo fungicides and Poncho seed treatments for cereals, fruits, vegetables and non-crop pest control. The company operates globally across North America, Europe, Africa, Middle East, Asia-Pacific and Latin America, with approximately 96,000 employees and 2024 sales of €46.6 billion. Founded in 1863 in Barmen, Germany, by Friedrich Bayer, it is headquartered in Leverkusen, Germany. Recent developments include the September 2025 agreement to divest anti-infective Avelox globally, closing expected in Q1 2026; the August 2025 partnership with Kumquat Biosciences worth up to $1.3 billion for a KRAS G12D inhibitor oncology candidate targeting pancreatic, colorectal and lung cancers; submission of registration applications in October 2025 for novel herbicide icafolin-methyl in four major markets with launch planned from 2028 and peak sales potential of €750 million; extension of microbial nitrogen fixation collaboration with Ginkgo Bioworks; major expansion of satellite imagery access via Planet partnership in February 2025 for agricultural digital innovation; Q3 2025 sales of €9.7 billion with growth in Crop Science vegetable seeds and Pharmaceuticals brands like Nubeqa and Kerendia; and upcoming Board changes with Dr. Judith Hartmann appointed CFO effective June 2026, succeeding Wolfgang Nickl.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk

  • businesswire.com

    Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

  • zacks.com

    Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD

  • businesswire.com

    Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

  • businesswire.com

    U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

  • zacks.com

    BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?

  • wsj.com

    Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion

  • reuters.com

    Bayer to invest $2.2 billion in new US pharma site

  • businesswire.com

    Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

  • reuters.com

    Bayer faces trial test of remaining Roundup claims after US Supreme Court win

  • wsj.com

    Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million

  • zacks.com

    FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia

  • businesswire.com

    Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

  • reuters.com

    Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement

  • reuters.com

    Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court

  • businesswire.com

    Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

  • zacks.com

    Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC

  • businesswire.com

    U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

  • businesswire.com

    Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production

  • businesswire.com

    BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION